AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01512394 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no bowel prep
Description: no bowel prep
Study NCT03471754 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TESA-HB Transcranial Electronic Stimulation Device
Description: Duration of treatment: 50 Minute Therapy sessions administered one time each day, for two 5-day cycles
Study NCT01439425 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss
Description: The low-calorie diet was designed to achieve a loss of 5-10% of initial body weight. The caloric restriction was 500 kcal below the resting energy expenditure, as evaluated by the Harris-Benedict equation. Intervention group patients received a balanced diet scheme, based on a caloric intake reduction related to BMI and sex (range: 1200-1500 kcal/d for women, 1300-1600 kcal/d for men).
Study NCT00961805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance
Description: Belly dance classes twice a week for 16 weeks. Each class had a maximum of eight students. The classes were administered by a physiotherapist with eight years of experience in belly dance. Classes began with a warm-up exercise, followed by the predetermined movements for the day, choreography and a cool-down exercise. The participants received a compact disc with music and an exercise book with the history and movements proposed for the program. Beginning in the fourth week, a set sequence of movements in the form of choreography was established for memorization and training at home.
Study NCT00961805 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Control Group
Description: The control group did not receive any intervention. They attended all assessments and remained on the waiting lis (after the end of the study was offered to this group the same treatment in the intervention group).
Study NCT02824289 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sun Safe Workplaces Program
Description: The intervention began by sending a Program Announcement Packet and requesting the first face-to-face meeting. At the first meeting, intervention staff covered: 1) Introduction to SSW; 2) Sun Safety Practices in the Workplace; 3) Sun Safety Policy for Outdoor Workers; 4) Sun Safety Policy Adoption; 5) Sun Safety Policy Reinforcement and Maintenance. They presented the SSW Website and a Sun Safety Tool Box. Following the first meeting, the manager scheduled Sun Safety Training by intervention staff with various employee groups. Workplace Sun Safety Materials were sent in four sets (twice a year over two years) for distribution to employees. Research staff made monthly Follow-up Contacts with managers.
Study NCT02824289 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Research staff sent printed materials on occupational sun safety to local government organizations twice. These included posters with personal protection messages and skin cancer rates, risk assessment brochures, worksite guides, total skin self-examination CD-Rom, the American Academy of Dermatology SPOT bookmark, and a sun safety tip card from the Occupational Safety and Health Administration (OSHA). Staff made presentations on general sun safety topics (not policy) at state professional conferences.
Study NCT02949271 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Programmed Intermittent Epidural Bolus
Study NCT02949271 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Epidural Infusion
Study NCT02949271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Study NCT02949271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Study NCT04631380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRAYER
Description: THE PRAYER GROUP WILL RECEIVE ABSOLUTELY THE SAME CARE AS THE CONTROL GROUP PLUS PRAYERS
Study NCT04196348 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Short BPL RYGB
Description: Alimentary limb (AL) with 120 cm and BPL with 100 cm.
Study NCT04196348 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long BPL RYGB
Description: AL with 120 cm and BPL with 200 cm.
Study NCT01053091 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: The trained subjects will be trained on a bicycle ergometer at about 60-70%of heart rate reserve for 35-55 minutes (that will include 10-min warm-up, 15-35-min main exercise, and 10-min cool-down) per day, 3 days per week for 12 weeks
Study NCT01599689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirrors Intervention
Description: Coaching in the use of two types of mirrors to support mental status and attention, physical mobility, and sense of body awareness and ownership, as well as patient dignity and privacy in self-care.~To be administered at set times and in a standardised way by ICU nursing and physical therapy teams.
Study NCT03852524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Description: Randomization of methylnaltrexone to placebo will be at a 1:1 ratio. Those receiving methylnaltrexone (study drug) will receive a subcutaneous dose pre-surgery and daily for three days following surgery.
Study NCT03852524 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomization of methylnaltrexone to placebo will be at a 1:1 ratio. Those receiving placebo will receive a subcutaneous dose pre-surgery and daily for three days following surgery.
Study NCT02697617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone
Study NCT02697617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01460381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Study NCT01460381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinidine
Study NCT04074551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1701
Description: HCP1701
Study NCT04074551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Losartan
Study NCT04074551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine
Study NCT04074551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin and Ezetimibe
Description: Rosuvastatin and Ezetimibe
Study NCT01386086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole
Description: The starting dose of aripiprazole will be 2 mg and the dose adjusted to a maximum of 15 daily
Study NCT03738657 — intervention group
Intervention type: OTHER
Intervention: Olfactory screening
Description: Therefore prior to gustatory testing, patients will be screened and assessed as having either normal or abnormal olfactory function using the Sniffin' Sticks (Burghart; Wedel, Germany). The test consists of 12 odour pens which represent every-day odours (peppermint, fish, coffee, banana, orange, rose, lemon, pineapple, cinnamon, cloves, leather and liquorice). Patients are presented with an odour and select the perceived smell using a multiple-forced-choice method.
Study NCT03738657 — intervention group
Intervention type: OTHER
Intervention: Quantative Gustatory Testing using Taste Strips
Description: Following screening for olfactory function, whole mouth gustatory function will be assessed using validated taste strips (Burghart; Wedel, Germany). Filter paper test strips are impregnated at one end with 2cm2 of either sweet, sour, salty or bitter taste solutions in four concentrations. In a pseudo-randomised sequence, individual strips will be placed on the tongue and patients will be asked to close their mouth in order to assess whole mouth function. Through a forced-choice procedure patients will be asked to identify the taste stimuli. Scores for individual taste qualities will range from 0-4 and an overall taste score will range from 0-16.~Patients will rinse their mouth with tap water prior the application of each taste strip.
Study NCT03303105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-48125
Description: TEV-48125 will be administered subcutaneously once every 4 weeks.
Study NCT03303105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-48125
Description: TEV-48125 will be administered subcutaneously once every 12 weeks.
Study NCT03610477 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Medium chain triglycerides
Description: Gel capsules, each containing 1 gram
Study NCT03610477 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Long chain triglycerides
Description: Gel capsules, each containing 1 gram
Study NCT00515840 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Physiotherapist
Description: Physiotherapist administered breathing retraining programme
Study NCT02823743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Daily medication
Study NCT02823743 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily intake
Study NCT03837925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40mg Tablet
Description: Patient participation for 6 weeks of treatment
Study NCT03837925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Patient participation for 6 weeks of treatment
Study NCT03193346 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A (BOTOX®) 155U to 195U IM injections in head/neck areas.
Study NCT03193346 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (sodium chloride 0.9 mg)
Description: Placebo matching BOTOX® \[Sodium chloride 0.9 mg\] IM injections in head/neck areas.
Study NCT03371108 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gan & Lee Insulin Glargine Injection
Description: Route of administration: subcutaneous injection
Study NCT03371108 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lantus®
Description: Route of administration: subcutaneous injection
Study NCT00003750 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hu14.18-IL2 fusion protein
Study NCT03933917 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acute Normovolemic Hemodilution
Description: Following induction of anesthesia, the volume of blood to be removed during Acute Normovolemic Hemodilution was calculated using an established formula:V=Weight（Kg）×12-15（mL/Kg）;Blood to be removed was capped at： Vmax=EVB×(Hi-Hf)/Hav（EBV= estimated blood volume （male:70mL/Kg，female:65mL/Kg）；Hi= initial hemoglobin ；Hf=target Hb（ 10g/dL ）；Hav= the average of the initial and minimal allowable hemoglobin）.Ensure the volume of removed blood does not exceed the upper limit and Hb ≥10g/dL after blood removed.
Study NCT00305006 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CIMT)
Description: 90 hours
Study NCT00305006 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hand-Arm Bimanual Intensive Therapy (HABIT)
Description: 90 hours
Study NCT02311855 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Influenza vaccine
Description: Each participant will have a blood draw to measure the antibody titres influenza strains covered by the 2014-2015 influenza vaccine at three different time points:~Visit 1- Baseline/prior to vaccination Visit 2- 4-6 weeks post-vaccination Visit 3- end of influenza season (April-May)~At Visit 1, after the baseline blood draw, all participants will be vaccinated by Research staff in order to standardize the time from Baseline blood draw to vaccination. Participants aged 65 and older will be offered the extra strength version of the vaccine, which is usual care. Participants under the age of 65 will be given the usual strength vaccine. All patients will be given the intramuscular (IM) vaccine.
Study NCT03392077 — intervention group
Intervention type: OTHER
Intervention: No cervical dilatation
Description: after delivery of the baby cervix will be remain closed
Study NCT02890667 — intervention group
Intervention type: OTHER
Intervention: Incident cancer
Description: The number of incident cancer cases
Study NCT01050491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sitaxentan
Description: 100 mg once a day during one year. Bronchial fibroscopy
Study NCT01050491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, one per day, during one year. Bronchial fibroscopy
Study NCT04161027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 75mg
Description: Pregabalin 75 mg capsule
Study NCT04161027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo capsule
Study NCT00071396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath-1H
Description: 15 mg/day Continuous infusion by vein (IV) for 6 days then given twice a week for remaining three weeks as 30 mg injection under skin to complete one treatment course of 4 weeks.
Study NCT00071396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 IV infusion on day 1, then 500 mg/m\^2 on days 8, 15, and 22.
Study NCT02447562 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Platform NOMHADchronic
Description: Intervention group with a health Platform NOMHADchronic
Study NCT02447562 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Phone-based care group
Study NCT02447562 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care group
Study NCT01689168 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: Tobacco cessation counseling
Study NCT01689168 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Tobacco cessation counseling
Study NCT01689168 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chiropractic adjustment
Description: Full spine high velocity, low amplitude manipulation of the spine
Study NCT00494455 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous subcutaneous glucose monitoring
Description: continuous subcutaneous glucose monitoring for 72h
Study NCT02606045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant von Willebrand factor
Description: Group I will receive Arm A recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 of each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5 of each of two menstrual cycles, Cycles 3 and 4.~Group II will receive Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5, for each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm A, rVWF 40 IU/kg intravenously (IV) infusion on day 1 on each of two menstrual cycles, Cycles 3 and 4.
Study NCT02606045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tranexamic acid
Description: Group I will receive Arm A recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 of each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5 of each of two menstrual cycles, Cycles 3 and 4.~Group II will receive Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5, for each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm A, rVWF 40 IU/kg intravenously (IV) infusion on day 1 on each of two menstrual cycles, Cycles 3 and 4.
Study NCT02047227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pergoveris®
Description: Pergoveris (follitropin alfa and lutropin alfa) was administered subcutaneously once daily with a starting dose of 300 International Unit (IU) recombinant human follicular stimulating hormone (rhFSH)/ 150 IU recombinant human luteinizing hormone (rhLH) after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 millimeter (mm); 250 microgram (mcg) of r-hCG (Ovidrel) was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments while maintaining the 2:1 ratio of r hFSH to r-hLH in the Pergoveris group based on the subject's response per site standard clinical practice.
Study NCT02047227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GONAL-f®
Description: GONAL-f (r-hFSH) was self-administered subcutaneously once daily at a starting dose of 300 IU after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 mm; 250 mcg of r-hCG was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments based on the subject's response per site standard clinical practice.
Study NCT02047227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human chorionic gonadotrophin (r-hCG)
Description: On r-hCG day, 250 mcg of r-hCG was administered once subcutaneously
Study NCT02047227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human chorionic gonadotrophin (r-hCG)
Description: On r-hCG day, 250 mcg of r-hCG was administered once subcutaneously
Study NCT02149875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dl-3-n-butylphthalide
Description: Intravenous infusion of 100 ml dl-3-n-butylphthalide and sodium chloride injection for 10 days, twice daily.
Study NCT02149875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Description: Intravenous infusion of 30 ml Cerebrolysin per day in 100 ml normal saline for 10 days.
Study NCT02149875 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 ml saline intravenous infusion once daily for 10 days.
Study NCT03144531 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Intervention for Kids and Parents (SKIP)
Description: Dyadic approach using self-efficacy theory to set goals, anticipate barriers, problem solve
Study NCT00753428 — intervention group
Intervention type: OTHER
Intervention: Community-based Survey
Description: Questionnaires will be used to record detailed information regarding demographic and socioeconomic characteristics, maternal medical history, recent obstetrical history (including access to preventive services for mother-to-child HIV transmission), and infant medical history. Infant deaths will also be recorded as part of the survey. In cases where either the mother or infant has died, we will perform verbal autopsy interviews (Appendix 5) with surviving family members to determine cause of death and gather information regarding HIV infection and/or exposure.~Heel/finger pricks will be taken so as to perform dried blood spot cards, and test for HIV in children and adults.
Study NCT02252445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol will be administered.
Study NCT02252445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane will be administered.
Study NCT00676741 — intervention group
Intervention type: DRUG
Intervention: insulin aspart
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study NCT00676741 — intervention group
Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study NCT00676741 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study NCT03135340 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WALANT
Description: These patients will receive local anesthetic for flexor tendon repair injected directly into the operative site on the hand. The local anesthetic used 1% lidocaine with 1:100,000 epinephrine.
Study NCT03135340 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General/regional anesthesia
Description: These patients will receive general/regional anesthesia for flexor tendon repair. This is ropivacaine 0.5% injected by an anesthetist under image-guidance in the axillary region of the arm. If the regional anesthesia is not functioning at the time of OR, this is converted to a general anesthetic as per standard protocol.
Study NCT03135340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WALANT Injection
Description: 1% lidocaine with 1:100,000 epinephrine injected directly into operative site. The typical quantity is 5-10cc aliquots.
Study NCT03135340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regional Anesthetic Injection
Description: 0.5% ropivacaine injected under ultrasound guidance into the axilla. The typical quantity is 30-40cc aliquots.
Study NCT03581994 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: DDI Test Report
Description: Test results of simulated patients
Study NCT00516087 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Genetically modified CTLs
Description: LMP1- and LMP2-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~Three different dosing schedules will be evaluated. Each patient will receive two injections, 14 days apart, according to the following dosing schedules:~Group One Day 0 2x10\^7 cells/m2 Day 14 2x10\^7 cells/m2~Group Two Day 0 2x10\^7 cells/m2 Day 14 1x10\^8 cells/m2~Group Three Day 0 1x10\^8 cells/m2 Day 14 2x10\^8 cells/m2
Study NCT02802462 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIT
Description: 3-minute intervals at 40% and 80%VO 2max